Norroy Bioscience, a China-based clinical-stage biotechnology startup focused on innovative targeted radiopharmaceutical...
Shanghai Henlius Biotech has entered into a strategic collaboration with Sandoz, a global leader in generics and bi...
The 2026 CDISC China Interchange has brought clinical research data specialists and industry stakeholders together in Sh...
Asia-Pacific continues to attract investment across pharmaceutical manufacturing, biotechnology, vaccines, advanced ther...
Asia-Pacific is moving from being viewed primarily as a later-stage commercial market to becoming a more important sourc...
The 2026 Global Health Summit opened in Hong Kong with a focus on moving scientific and healthcare innovations from rese...
Ascletis Pharma has initiated two Phase I studies in the United States evaluating investigational once-monthly injectabl...
Innovent Biologics, Inc. and Daiichi Sankyo have entered into an exclusive agreement for the commercialisation of Vanfly...
Long-term diabetes management requires continuous blood glucose monitoring to detect abnormalities early and intervene i...
CSPC Pharmaceutical Group has entered into a contract with AstraZeneca in relation to the establishment of a joint ...
Counterfeit and unauthorised healthcare products remain a persistent risk across Asia, particularly where fragmented dis...
AsymBio, a China-based biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of ...
Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals have reported positive Phase IIa results for vortos...
Shanghai Ark Biopharmaceutical, or ArkBio, has completed dosing across all healthy-volunteer cohorts in an Australian Ph...
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration to b...
Antengene has received a $60 million upfront payment from UCB under a worldwide exclusive licensing agreement for ATG-20...
Kelun-Biotech has received approval from the Center for Drug Evaluation of China’s National Medical Products Admin...
Hong Kong headquartered Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discover...
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymche...
A growing burden demands a new approach Cardiac ablation treats AFib by targeting heart cells that send erratic signals...
Harbour BioMed, a US-based biopharmaceutical company, has entered into a strategic collaboration with China Nationa...
Takeda China has announced that the National Medical Products Administration (NMPA) has approved the use of ORZEYFUL (ov...
It is estimated that by 2040 China-originated treatments will represent 35% of US FDA approvals. When marketing treatmen...
Gerresheimer, an innovative system and solution provider and global partner to the pharma, biotech, and cosmetic industr...
Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals have reported positive Phase 2a data for vortosiran, an...
